Health Sciences Journal Articles
Permanent URI for this collection
Browse
Recent Additions
Item [89Zr]Zr-Girentuximab PET/CT for the targeted diagnosis of clear cell renal cell carcinoma (ccRCC)(Australian and New Zealand Society of Nuclear Medicine, 2023-09-09) Painting, A.; Vyas, Madhusudan; Fagan, J.; Lim, R.; Unitec, Te Pūkenga; Mercy Radiology (Auckland, N.Z.); Te PūkengaccRCC Patient 89Zirconium Girentuximab Procedure Pulmonary emboli Pelvic embolic Right teres muscle Conclusion ReferencesItem Nuclear medicine applications in prostate cancer(StatPearls, 2023-05-30) Vyas, Madhusudan; Leslie, S.; Unitec, Te Pūkenga; Te Pukenga; Creighton UniversityIn recent years, the incidence of prostate cancer has been the highest ever recorded due to earlier and more accurate detection and an increase in the average lifetime. Prostate cancer is now the second most common malignancy amongst all cancers in men and the fourth most common overall. The American Cancer Society has identified prostate cancer as the second leading cause of mortality from oncological causes in the United States, accounting for an estimated 268,490 newly diagnosed cases and 34,500 deaths in 2022. The National Cancer Institute predicts that the average American man has an 11% risk of being diagnosed with prostate cancer at some point in life and a 2.5% overall risk of dying from the disease. Globally, there were more than 1.4 million new cases of prostate cancer diagnosed worldwide in 2020, accounting for 375,304 deaths.[1][2][3] Prostate cancer has been identified as the most commonly diagnosed malignancy in 112 countries worldwide and the leading cause of cancer mortality in 48.[2][4] Timely diagnosis leading to earlier and more effective treatment is required to reduce the significant morbidity and mortality rates. Nuclear medicine has several new and revolutionary prostate cancer detection, localization, staging, and treatment tools utilizing targeted therapy.[5][6] The expanding role nuclear medicine plays in managing prostate cancer will be discussed in detail in the following review. [...] Radiopharmaceuticals for Bone Scan Imaging Tc-99m Diphosphonates (99mTc-MDP) Bone Scan [F-18] F-18-Sodium Fluoride Bone Scan Radiopharmaceuticals for Prostate Cancer Imaging [F-18] F-Fluciclovine (FACBC) PET Scan PSMA-Binding Radionuclide Imaging [Ga-68] Ga-68-PSMA-11 [F-18] F-18-PSMA piflufolastat (DCFPyL) Tc-99m-PSMA Radioligands Indium-111 Capromab Pendetide Imaging Tips for PSMA-PET Interpretation Challenges to PSMA-PET Interpretation Summary: PET-Based Radionuclide Imaging in Prostate Cancer Targeted Radiopharmaceutical Therapy for Prostate Cancer (Theranostics) Lutetium-177 Radioligand Therapy Patient Selection for Lu-177-PSMA Treatment Treatment Protocols for Lu-177-PSMA Therapy Other PSMA Ligand Therapies Other Nuclear Medicine Therapies in Prostate Cancer Summary of Principal Therapeutic Targeted RadiopharmaceuticalsItem A comprehensive chemical and nutritional analysis of New Zealand yacon concentrate(MDPI (Multidisciplinary Digital Publishing Institute)B, 2022-12-23) Chessum, K.; Chen, T.; Kam, R.; Yan, Mary; Auckland University of Technology; Unitec, Te Pūkenga; Te PūkengaGlobal interest in yacon (Smallanthus sonchifolius) is growing due to its potential as a functional food, attributable to its unique profile of bioactives and high fructooligosaccharide (FOS) content, which vary between cultivars. Our objective was to conduct a comprehensive chemical and nutritional analysis of New Zealand yacon concentrate (NZYC)—a sweet syrup derived from the roots of cultivar ‘New Zealand’, which was first grown in the 1980s. The major minerals in NZYC were potassium, phosphorus, and calcium. The FOS content ranged from 17.6 to 52.7 g/100g. Total phenolic content ranged from 565 to 785 mg gallic acid equivalents per 100 g; chlorogenic acid and caffeic acid were the major phenolic compounds. The major amino acids were L-arginine, L-glutamic acid, L-proline, L-aspartic acid, and asparagine. The major organic acids were citric, malic, quinic, and fumaric acids. Antioxidant activity ranged from 1084.14 to 3085.78 mg Trolox equivalents per 100 g depending on the assay used. The glycaemic index (GI) value was 40 ± 0.22, classifying it as a low-GI food. These results support the classification of NZYC as a nutraceutical food product for future diet therapy applications.Item Yacon concentrate NZFOS+, its phytochemical contents, health-related properties and potential applications(MDPI (Multidisciplinary Digital Publishing Institute), 2022-05-24) Yan, Mary; Permal, R.; Quach, E.; Chessum, K.; Kam, R.; Unitec Institute of Technology; Auckland University of TechnologyYacon (Smallanthus sonchifolius), a sustainable foodstuff, is perceived as a functional food because it contains biologically active components, e.g., fructooligosaccharides (FOS), inulin, and phenolic compounds that may provide physiological benefits beyond basic nutrition to reduce the risk of chronic diseases. There is a growing public interest in why and how to use yacon. Yacon, originally from South America, has been grown in New Zealand (NZ) since the 1980’s. NZ-produced yacon concentrate NZFOS+ contains the purest natural prebiotic FOS. Our study aimed to examine the phytochemical contents of NZFOS+ and its health-related properties. The glycemic index of yacon concentrate was measured by ISO 26642:2010(E) (n = 10). Total phenolic and flavonoid contents were measured by the spectrometric method. The chlorogenic acid content and phenolic profiling were measured using the liquid chromatography coupled with mass spectrometry (LC-MS). The antioxidant activity of the yacon concentrate and Manuka honey were compared using the cupric reducing antioxidant capacity (CUPRAC), ferric ion reducing antioxidant power (FRAP), and 2,2-diphenyl-1-picrylhydrazyl (DPPH) assays. The results indicated that compared to Manuka honey, yacon concentrate has a lower glycemic index (40 vs. 52); a higher content of total phenolic (5430 mg vs. 744 mg GAE/100 g), total flavonoid (329 mg vs. 22 mg QE/100 g), and chlorogenic acid (11.88 μg vs. 0.08 μg CA/g); and across all assays observed, a significantly higher antioxidant capacity (CUPRAC assay, 892 mg vs. 52.6 mg TE/100 g; FRAP assay, 633 mg vs. 47 mg TE/100 g; DPPH assay, 383 mg vs. 22 mg TE/100 g, respectively). Yacon concentrate has proven potential health benefits and applications associated with the maintenance of health and wellbeing and prevention of chronic diseases. Further investigations are needed for human studies and new applications and use of yacon concentrate. Yacon concentrate (NZFOS+) has potential markets in the development of new food products and new diet therapy applications, e.g., in the form of syrup, and functional prebiotic drinksItem Asbestos and other hazardous fibrous minerals: Potential exposure pathways and associated health risks(Multidisciplinary Digital Publishing Institute, 2022-03-29) Berry, Terri-Ann; Belluso, E.; Vigliaturo, R.; Giere, R.; Emmett, E.A.; Testa, J.R.; Steinhorn, Gregor; Wallis, Shannon; Unitec Institute of Technology; University of Torino; University of Pennsylvania; Fox Chase Cancer CenterThere are six elongate mineral particles (EMPs) corresponding to specific dimensional and morphological criteria, known as asbestos. Responsible for health issues including asbestosis, and malignant mesothelioma, asbestos has been well researched. Despite this, significant exposure continues to occur throughout the world, potentially affecting 125 million people in the workplace and causing thousands of deaths annually from exposure in homes. However, there are other EMPS, such as fibrous/asbestiform erionite, that are classified as carcinogens and have been linked to cancers in areas where it has been incorporated into local building materials or released into the environment through earthmoving activities. Erionite is a more potent carcinogen than asbestos but as it is seldom used for commercial purposes, exposure pathways have been less well studied. Despite the apparent structural and chemical similarities between asbestos and fibrous erionite, their health risks and exposure pathways are quite different. This article examines the hazards presented by EMPs with a particular focus on fibrous erionite. It includes a discussion of the global locations of erionite and similar hazardous minerals, a comparison of the multiple exposure pathways for asbestos and fibrous erionite, a brief discussion of the confusing nomenclature associated with EMPs, and considerations of increasing global mesothelioma cases.